1. Hepatitis web study Hepatitis web study Peginterferon alfa-2a + RBV versus Interferon alfa-2a + RBV ACTG 5071 Phase 2 Treatment Naïve, Chronic HCV and HIV Chung RT, et. al. N Engl J Med. 2004;351:451-9.

2. Hepatitis web study PEG alfa-2a + RBV versus IFN alfa-2a + RBV in HCV & HIV ACTG 5071 Study: Features Study - Randomized, placebo-controlled, phase 2 trial - Conducted at 21 ATG sites in United States Subjects - N = 133 chronically infected with both HCV and HIV - Treatment naïve - 78% genotype 1 Regimens (48 Week Treatment) - Peginterferon alfa-2a 180 µg 1x/week + Ribavirin (dose escalation) - Interferon alfa-2a: 6 million IU 3x/week, then 3 million IU 3x/week + Ribavirin (dose escalation) Primary Endpoint - Undetectable HCV RNA (< 50 IU/ml) 24 weeks after stopping Rx Source: Chung RT, et. al. N Engl J Med. 2004;351:451-9.

3. Hepatitis web study Peginterferon alfa-2a + Ribavirin Interferon alfa-2a + Ribavirin 48720 Week Source: Chung RT, et. al. N Engl J Med. 2004;351:451-9. PEG alfa-2a + RBV versus IFN alfa-2a + RBV in HCV & HIV ACTG 5071 Study: Design Drug Dosing Peginterferon alfa-2a 180 µg 1x/week x 48 weeks Interferon alfa-2a 6 million IU 3x/week x 12 weeks, then 6 million IU 3x/week x 36 weeks Ribavirin (divided bid): 600 mg/day x 4 weeks, then 800 mg/day x 4 weeks, then 1000 mg/day x 40 weeks SVR24 N = 66 N = 67

4. Hepatitis web study PEG alfa-2a + RBV versus IFN alfa-2a + RBV in HCV & HIV ACTG 5071 Study: Results ACTG 5071 Study: Virologic Responses by Treatment Regimen Source: Chung RT, et. al. N Engl J Med. 2004;351:451-9. 8/6727/668/6718/66

5. Hepatitis web study PEG alfa-2a + RBV versus IFN alfa-2a + RBV in HCV & HIV ACTG 5071 Study: Results ACTG 5071 Study: SVR24 by Treatment Regimen and Genotype Source: Chung RT, et. al. N Engl J Med. 2004;351:451-9. 8/6718/663/527/515/1511/15

6. Hepatitis web study SVR N = 21 (49%) N = 21 (49%) N = 22 (51%) N = 22 (51%) N = 63 (59%) N = 43 (42%) 2-log drop or undetectable HCV RNA Yes No Week 12 HCV RNA (N = 106) Week 12 HCV RNA (N = 106) N = 63 (100%) N = 63 (100%) N = 0 (0%) N = 0 (0%) No SVR SVR No SVR Source: Chung RT, et. al. N Engl J Med. 2004;351:451-9. PEG alfa-2a + RBV versus IFN alfa-2a + RBV in HCV & HIV ACTG 5071: Predictive Value of Early Virologic Response

7. Hepatitis web study Source: Chung RT, et. al. N Engl J Med. 2004;351:451-9. PEG alfa-2a + RBV versus IFN alfa-2a + RBV in HCV & HIV ACTG 5071 Study: Conclusions Conclusions: “In persons infected with HIV, the combination of peginterferon and ribavirin is superior to the combination of interferon and ribavirin in the treatment of chronic hepatitis C. These regimens may provide clinical benefit even in the absence of virologic clearance. The marked discrepancy in the rates of sustained virologic response between HCV genotypes indicates that strategies are needed to improve the outcome in persons infected with HCV genotype 1.”

8. Hepatitis web study Hepatitis web study This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Online www.hepatitisc.uw.edu www.hepatitisc.uw.edu Hepatitis Web Study http://depts.washington.edu/hepstudy/ http://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Online www.hepatitisc.uw.edu www.hepatitisc.uw.edu Hepatitis Web Study http://depts.washington.edu/hepstudy/ http://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.